2-(4-Propylphenyl)ethanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-Propylphenyl)ethanamine
• 化学式: C₁₁H₁₇N
• 分子量: 163.26
• InChiKey: XYWGVXQTEKNATH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Dendrimer based compositions and methods of using the same
  申请人：William Bernell

  公开号：US20070041934A1

  公开（公告）日：2007-02-22

  The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and monitoring the response to therapy of a cell or tissue (e.g., a tumor).

  本发明涉及一种新型的治疗和诊断树状分子。具体而言，本发明涉及基于树状分子的组合物和系统，用于疾病诊断和治疗（例如癌症诊断和治疗）。该组合物和系统包括一种或多种用于靶向、成像、感知和/或提供治疗或诊断材料以及监测细胞或组织（例如肿瘤）对治疗的反应的组分。
• DENDRIMER BASED COMPOSITIONS AND METHODS OF USING THE SAME
  申请人：Baker, JR. James R.

  公开号：US20090088376A1

  公开（公告）日：2009-04-02

  The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and monitoring the response to therapy of a cell or tissue (e.g., a tumor).

  本发明涉及新型治疗和诊断树状分子。具体而言，本发明涉及基于树状分子的组合物和系统，用于疾病诊断和治疗（例如癌症诊断和治疗）。该组合物和系统包括一个或多个成分，用于靶向、成像、感知和/或提供治疗或诊断材料，并监测细胞或组织（例如肿瘤）对治疗的反应。
• Neue Sulfonyl-phenylalkylamine, Verfahren zu ihrer Herstellung sowie Arzneimittel
  申请人：BOEHRINGER MANNHEIM GMBH

  公开号：EP0221344B1

  公开（公告）日：1990-05-23
• PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1131290B1

  公开（公告）日：2008-02-20
• METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY
  申请人：MATA Nathan L.

  公开号：US20090098145A1

  公开（公告）日：2009-04-16

  Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. Provided are methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.